TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04866134
Drug: ERAS-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERAS-007 will be administered orally as specified in Arm description.
Study: NCT04866134
Drug: ERAS-601
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERAS-601 will be administered orally as specified in Arm description.
Study: NCT04928222
Drug: Placebo-containing MNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
Study: NCT06571461
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: Oral
Study: NCT04840745
Drug: CKD-841 A-1 3.75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection, subcutaneous injection
Study: NCT04840745
Drug: CKD-841 A-1 1.88mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection, subcutaneous injection
Study: NCT04840745
Drug: CKD-841 D 2.92mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection, subcutaneous injection
Study: NCT04840745
Drug: Leuplin Inj. 3.75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection, subcutaneous injection
Study: NCT05199090
Drug: MBL949
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injections administered for 14 weeks
Study: NCT05458193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet for oral use
Study: NCT05622591
Drug: ELU001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
Study: NCT05199090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator to MLB949
Study: NCT04720534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: calculated volume to match active treatment by sc injection
Study: NCT05061446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks
Study: NCT05211622
Drug: 1. alpha acid lipoic - tables
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days
Study: NCT05211622
Drug: 2. ozonated oil - mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks
Study: NCT05414240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
Study: NCT05383170
Drug: CyPep-1
Normalized name: Cypex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection
Study: NCT04901884
Drug: PET/MR with 18F-FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
Study: NCT05995444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)
Study: NCT06349044
Drug: Oxaliplatin and Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14
Study: NCT06349044
Drug: Anti-VEGF 15mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 15mg/kg d1 iv q3w
Study: NCT06349044
Drug: Anti-VEGF 7.5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5mg/kg d1 iv q3w
Study: NCT06265220
Drug: AB-101
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK Cell Therapy
Study: NCT06265220
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy
Study: NCT05148026
Drug: Unfractionated heparin first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomized to receive this sequence of anticoagulation regimens: UFH / UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA
Study: NCT04819360
Drug: Botox 100 UNT Injection
Normalized name: Botox 100 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection of Botox® 100 UNT
Study: NCT05126888
Drug: SCI-110
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
Study: NCT05443984
Drug: JP-1366 20mg
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)
Study: NCT06317805
Drug: Standard of Care - Double Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
Study: NCT06531707
Drug: Ibuprofen + Loratadine fixed dose
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day
Study: NCT06531707
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Suspension 2,000 mg / 100 mL, 20 mL twice a day
Study: NCT05457270
Drug: AZD4831
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 of Period 2. Each period lasts for 8 days.
Study: NCT04374474
Drug: corticosteroid nasal irrigation
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).
Study: NCT05484401
Drug: Ibuprofen 200Mg Oral Cap
Normalized name: IBUPROFEN 200MG ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 200mg Liquid Capsules once in 12 hours
Study: NCT05484401
Drug: Ibuprofen 200Mg Oral Tablet
Normalized name: Ibuprofen 200mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 200mg Tablets once in 12 hours
Study: NCT04878705
Drug: TWP-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single subcutaneous injection
Study: NCT04878705
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single subcutaneous injection
Study: NCT06391827
Drug: DA-7503 Single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).
Study: NCT06391827
Drug: Placebo Single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administraion for once.
Study: NCT06391827
Drug: Placebo Multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily for 7 days
Study: NCT05322603
Drug: Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: A decrease in the pain severity (VAS);opioid-sparing effect
Study: NCT05322603
Drug: Analgesics
Normalized name: ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A decrease in the pain severity (VAS)
Study: NCT00863538
Drug: KPS-0373
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05160805
Drug: ONL1204 Ophthalmic solution (Dose A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation administered by intravitreal (IVT) injection
Study: NCT05663398
Drug: Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, a nonsteroidal anti-inflammatory drug
Study: NCT05663398
Drug: Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, a nonsteroidal anti-inflammatory drug
Study: NCT04825223
Drug: Multicomponent Meningococcal B Vaccine
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
Study: NCT04825223
Drug: Meningococcal Group B Vaccine MenB
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
Study: NCT04825223
Drug: Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
Study: NCT04825223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
Study: NCT04590547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo looks like GLS-1027
Study: NCT06406205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
Study: NCT05435573
Drug: 1000 mL of ringer's acetate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL of ringer's acetate solution
Study: NCT06205290
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06293417
Drug: Dose escalation of moderate-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group
Study: NCT05768503
Drug: Experimental drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
Study: NCT06531759
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl soaked nasal packs.
Study: NCT06429306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl triethyl citrate
Study: NCT05039905
Drug: 99mTc-MSA-ICG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
Study: NCT04902105
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsules
Study: NCT04760275
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT).
Study: NCT06664008
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.
Study: NCT04372615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive IV matching placebo on Day 1 and Day 15,
Study: NCT05044234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral
Study: NCT04901117
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use according to the drug combination options selected by each center.
Study: NCT04901117
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use according to the drug combination options selected by each center.
Study: NCT04528563
Drug: Ketorolac Tromethamine 10 MG/ML
Normalized name: ketorolac tromethamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Steroidal-Anti-Inflammatory given intravenously.
Study: NCT05294263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching, inactive medication
Study: NCT06026566
Drug: Dos of Afentanil 50
Normalized name: purified protein derivative of tuberculin 50 UNT/ML [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: the dosage of Afentanil is 50 ng/ml for TCI
Study: NCT06435026
Drug: FTC/TDF 200mg/300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose
Study: NCT06435026
Drug: FTC/TDF 300mg/450mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150% Standard Dose
Study: NCT06435026
Drug: FTC/TDF 400mg/600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200% Standard Dose
Study: NCT06404177
Drug: Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular injection of piroxicam with a perfusion of isotonic saline intravenous
Study: NCT04978038
Drug: mRNA- COVID-19
Normalized name: COVID-19 VACCINE MRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
Study: NCT05372198
Drug: Chohort 2: Immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
Study: NCT05130567
Drug: LP-128 capsules
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing with LP-128 capsules
Study: NCT05077254
Drug: SOC IS Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.
Study: NCT05077254
Drug: SOC IS Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.
Study: NCT05855200
Drug: CAPEOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPEOX will be administered.
Study: NCT05855200
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX will be administered.
Study: NCT06394128
Drug: Cangpo Liujun Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on the diagnostic criteria of spleen deficiency and dampness excess syndrome, Cangpo Liujun Prescription could be used to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy.
Study: NCT05468840
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: see study arm description
Study: NCT05932290
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT05916755
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard NACT will be given.
Study: NCT05378867
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus.
Study: NCT05297045
Drug: RGT001-075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GLP1 Receptor Agonist
Study: NCT06396065
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
Study: NCT06168175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous, daily for 5 consecutive days
Study: NCT05434897
Drug: AK3280 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
Study: NCT05434897
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
Study: NCT04725175
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple ascending oral doses of matching Placebo tablets
Study: NCT05035979
Drug: BaidI Quzhi granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
Study: NCT05035979
Drug: Ju Yin cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
Study: NCT05035979
Drug: Baidi Quzhi placebo granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
Study: NCT05035979
Drug: Ju Yin placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
Study: NCT05658692
Drug: glucocorticoid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.~Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours).
Study: NCT05658692
Drug: Muscle relaxant therapy
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
Study: NCT05658692
Drug: statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Simvastatin: 80mg qd po for not more than 28days;~2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died.
Study: NCT05658692
Drug: Sedative analgesia/muscle relaxant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
Study: NCT05658692
Drug: inotropes therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.
Study: NCT05897216
Drug: CKD-501, D745, D150, D029
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06664060
Drug: osteoimplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 lower third molars will be selected and prescribed preoperative treatment with two units of Osteoimplant Complex® 5 days prior to surgery and postoperative treatment with one unit of Osteoimplant® for 8 weeks from the time of surgery. Both nutritional supplements will be administered every 24 hours.
Study: NCT06664060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 lower wisdom teeth will be selected and prescribed placebo, both preoperatively 5 days prior to surgery and postoperatively for 8 weeks from the time of surgery.
Study: NCT06662669
Drug: HY-0102
Approvals — FDA: no, EMA: no, PMDA: no
Description: HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.
Study: NCT06662877
Drug: Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m2,d1,iv.drip,Q2W + Leucovorin 400mg/m2,d1,iv.drip,Q2W+ Fluorouracil 2400 mg/m2 civ46h, Q2W
Study: NCT06428097
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
Study: NCT06428097
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
Study: NCT05025293
Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj
Normalized name: ZOLEDRONIC ACID 5MG/BAG 100ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml Zoledronic acid (5mg/100ml) administered intravenously
Study: NCT06183229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
Study: NCT02503280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ten 0.5 ml injections of phosphate-buffered saline \[PBS\] and 1% human serum albumin \[HSA\]).
Study: NCT05604729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution
Study: NCT05349669
Drug: Jafron use during CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of filter Jafron during CPB
Study: NCT04819685
Drug: KANG FU PEN
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays